Search results for "Progression"

showing 10 items of 1251 documents

Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus.

2007

Background and study aims Computed virtual chromoendoscopy (CVC) is a new imaging technique that enhances mucosal surface contrast and highlights the vascular pattern without the need for dye-spraying as in conventional chromoendoscopy. The aim of this prospective randomized pilot study with a crossover design was to compare CVC with conventional chromoendoscopy with acetic acid (CAA) for the detection of high grade intraepithelial neoplasia (HGIN) or early cancer in patients with Barrett's esophagus. Patients and methods 57 patients with Barrett's esophagus (mean length 3.8 cm) and a history of HGIN/early cancer or suspected HGIN/early cancer were randomly allocated to undergo either CAA o…

AdultMalemedicine.medical_specialtyTime FactorsEsophageal NeoplasmsAdministration TopicalBiopsyGastroenterologySensitivity and SpecificitySeverity of Illness IndexEndoscopy GastrointestinalChromoendoscopyBarrett EsophagusUser-Computer InterfaceInternal medicinemedicineHumansEsophagusIntestinal MucosaAcetic AcidAgedNeoplasm StagingRetrospective StudiesAged 80 and overIntraepithelial neoplasiamedicine.diagnostic_testbusiness.industryEsophageal diseaseGastroenterologyCancerReproducibility of ResultsMiddle Agedmedicine.diseasePrognosisEndoscopymedicine.anatomical_structureBarrett's esophagusHigh Grade Intraepithelial NeoplasiaDisease ProgressionFemaleIndicators and ReagentsRadiologybusinessPrecancerous ConditionsFollow-Up StudiesEndoscopy
researchProduct

Short-Term Prognosis of Juvenile Myocardial Infarction

2016

In our early research regarding the hemorheological pattern in patients with acute myocardial infarction (AMI) with a mean age of 61.45 + 10.99 years, we showed that the major hemorheological parameters were almost normalized 2 weeks after the acute event. In the last decade, we focused on hemorheological parameters in juvenile myocardial infarction (JMI), defined as AMI in patients aged 45 years, in the ‘‘Sicilian study on juvenile myocardial infarction’’. Juvenile myocardial infarction is responsible for 2% to 10% of all cases with AMI in different surveys. Juvenile myocardial infarction presents a typical pattern of risk factors and shows clinical, angiographic, and prognostic characteri…

AdultMalemedicine.medical_specialtyTime FactorsIschemic heart diseaseBlood viscosity030204 cardiovascular system & hematologyBlood rheology030218 nuclear medicine & medical imagingAnginaCoronary artery diseasePlasma03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusInternal medicinemedicineHumansMyocardial infarctionAge of OnsetRisk factorNon-ST Elevated Myocardial InfarctionBlood rheology; Myocardial infarction; Ischemic heart diseaseMedicine (all); Cardiology and Cardiovascular Medicinebusiness.industryMedicine (all)HemodynamicsBlood ViscosityPrognosismedicine.diseaseMyocardial infarctionHeart failureCoronary vesselDisease ProgressionCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessAngiology
researchProduct

Large left ventricular metastatis in patient with liposarcoma.

2014

Abstract Metastasis to the heart and pericardium are rare. We present a 44-year-old male with pleural dedifferentiated liposarcoma and multiple metastases, with no previous cardiological history and/or cardiac symptoms. A transthoracic echocardiogram during the advanced stage of disease showed a lobulated, large and mobile mass, with homogeneous echogenicity, attached to the basal posterior wall of the left ventricle via a broad base and with intracavitary growth. This mass extends to inferolateral and inferoseptal wall of the left ventricle.

AdultMalemedicine.medical_specialtyTime FactorsLarge left ventricular metastasiBiopsyHeart VentriclesPleural Neoplasms030204 cardiovascular system & hematologyDoppler echocardiographyLiposarcomaMetastasisHeart Neoplasms03 medical and health sciencesFatal Outcome0302 clinical medicineHumansMedicinePericardium030212 general & internal medicinePleural Neoplasmheart metastases liposarcomamedicine.diagnostic_testbusiness.industryEchogenicityGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEchocardiography DopplerTumor Burdenmedicine.anatomical_structureVentricleliposarcomaDisease Progressioncardiovascular systemRadiologyTransthoracic echocardiogramTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusiness
researchProduct

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

2013

Abstract Background In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. Methods Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. Results 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a high…

AdultMalemedicine.medical_specialtyTime FactorsProlineDecision MakingHepacivirusPharmacologyAntiviral AgentsSeverity of Illness IndexPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compoundFibrosisBoceprevirInternal medicineDrug DiscoveryRibavirinGenotypemedicineHumansDecompensationProspective StudiesWatchful WaitingAgedDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaPatient PreferenceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLogistic ModelschemistryTolerabilityMultivariate AnalysisDisease ProgressionDrug Therapy CombinationFemalebusinessOligopeptidesmedicine.drugDigestive and Liver Disease
researchProduct

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

2015

<b><i>Introduction:</i></b> The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. <b><i>Materials and Methods:</i></b> Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. <b><i>Results:</i></b> A total of 411 patients we…

AdultMalemedicine.medical_specialtyUrologyInternational CooperationAntineoplastic AgentsSettore MED/24 - UrologiaMedication AdherenceSocial lifeCohort StudiesRecurrenceInternal medicinemedicineHumansAgedBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgeryClinical PracticeRegimenAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsTreatment interruptionToxicityBCG VaccineDisease ProgressionIntravesical bcgPatient ComplianceFemalenon muscle invasive bladder cancer Bacillus Calmette Guèrin intravesical instillation immunotherapy compliance toxicityNeoplasm Recurrence LocalbusinessCohort studyUrologia internationalis
researchProduct

The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study.

2013

Background. Growing evidence indicates that vitamin D receptor activation may have antiproteinuric effects. We aimed to evaluate whether vitamin D supplementation with daily cholecalciferol could reduce albuminuria in proteinuric chronic kidney disease (CKD) patients. Methods. This 6-month prospective, controlled, intervention study enrolled 101 non-dialysis CKD patients with albuminuria. Patients with low 25(OH) vitamin D [25(OH)D] and high parathyroid hormone (PTH) levels (n = 50; 49%) received oral cholecalciferol (666 IU/day), whereas those without hyperparathyroidism (n = 51; 51%), independent of their vitamin D status, did not receive any cholecalciferol, and were considered as the co…

AdultMalemedicine.medical_specialtyUrologyRenal functionParathyroid hormoneAdministration OralCalcitriol receptorPhosphateschemistry.chemical_compoundYoung AdultChronic kidney diseaseEstadística e Investigación OperativaInternal medicinemedicineVitamin D and neurologyAlbuminuriaHumansProspective StudiesRenal Insufficiency ChronicVitamin DAgedCholecalciferolAged 80 and overTransplantationHyperparathyroidismbusiness.industryHyperparathyroidismVitaminsMiddle Agedmedicine.diseaseVitamin D DeficiencyEndocrinologychemistryNephrologyParathyroid HormoneDietary SupplementsAlbuminuriaDisease ProgressionFemalemedicine.symptomCholecalciferolbusinessKidney diseaseNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

2006

PURPOSE: We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. MATERIALS AND METHODS: NMP22 voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. RESULTS: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22 was 5.5 U/ml (range across institutions 2.5 to 1…

AdultMalemedicine.medical_specialtyUrologyUrinary systemnuclear matrix protein 22Urologytumor markers biologicalBladder NeoplasmBiomarkers TumorMedicineHumansStage (cooking)bladderAgedGynecologyAged 80 and overCarcinoma Transitional CellUrinary bladderBladder cancermedicine.diagnostic_testbusiness.industryCarcinoma in situNuclear ProteinsReproducibility of ResultsCystoscopyMiddle Agedmedicine.diseasemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsDisease Progressionbladder neoplasmFemaleNeoplasm Recurrence LocalbusinessThe Journal of urology
researchProduct

Conservative surgery of renal cell tumors in 140 patients: 21 years of experience.

1992

Operative method, course and complications were analyzed retrospectively in 140 patients who underwent a conservative operation for renal tumor between June 1969 and December 1990. In 53 patients (20 women and 33 men, mean age 61.2 years, range 38 to 77 years, with 49 renal cell carcinomas and 4 benign renal tumors) there was an imperative indication for an organ preserving operation because nephrectomy would have made dialysis obligatory. In 87 patients (29 women and 58 men, mean age 53.7 years, range 27 to 74 years, with 72 renal cell carcinomas and 15 benign renal tumors) the tumor was conservatively resected in the presence of a normal contralateral unit (elective indication) and 68 of …

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentEnucleationPostoperative ComplicationsRenal cell carcinomamedicineCarcinomaHumansSurvival rateCarcinoma Renal CellDialysisAgedNeoplasm StagingRetrospective StudiesKidneybusiness.industryMiddle Agedmedicine.diseaseNephrectomyKidney NeoplasmsSurgerySurvival Ratemedicine.anatomical_structureTumor progressionSurgical Procedures OperativeFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesThe Journal of urology
researchProduct

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic im…

1996

To analyze the effectiveness of adjuvant polychemotherapy after radical cystectomy for non-organ-confined transitional cell bladder cancer (Stages pT3b, pT4a, and/or pN1 or pN2).Of 166 consecutive patients undergoing cystectomy at two institutions from 1987 to 1993, 80 received adjuvant polychemotherapy with methotrexate, vinblastine, and cisplatin plus doxorubicin (MVAC) or epirubicin (MVEC), whereas 86 had cystectomy only. The patients were evaluated for relapse-free survival and length of progression-free interval on the basis of follow-up data obtained in 1995 and 1996.Kaplan-Meier analysis revealed a significantly higher progression-free rate for patients after adjuvant chemotherapy (P…

AdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansProspective StudiesProspective cohort studyLymph nodeAgedAged 80 and overChemotherapyCarcinoma Transitional CellUrinary bladderbusiness.industryMiddle Agedmedicine.diseasePrognosisSurgerymedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemalebusinessAdjuvantFollow-Up StudiesUrology
researchProduct